Sialic acid for assisted saliva flow

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and relates to disturbed salivation. A composition containing sialic acid for treating or preventing the diseases related to disturbed salivation contains a protein fraction containing 7 to 25 wt % of N-acetylneuraminic acid and threonine in the amount of 8 to 22% of total amino acids, wherein N-acetylneuraminic acid is bound to a threonine-enriched peptide-protein network.

EFFECT: invention enables increasing salivation, especially observed in elderly persons and accompanying such diseases as dysphagia, xerostomia and a combination thereof.

23 cl, 2 dwg

 

The present invention generally relates to the field of diseases associated with impaired salivation, and to compositions that can be used for the treatment or prevention of such diseases. One embodiment of the present invention relates to compositions containing sialic acid for the treatment and/or prevention of diseases associated with impaired salivary flow.

Many people live to old age in good health. But as aging in the body is a lot of functional and structural changes, and not every person can easily cope with these changes. The reasons for individual differences and diverse, and include genotype, nutrition and behavior.

Aging is associated with functional changes in neurons and progressive loss of neurons of the Central and peripheral nervous system.

A typical condition, often associated with age, is a feeling of dryness in the mouth, due to the deficiency of salivation.

A feeling of dryness in the mouth can be closely linked to problems with swallowing, which further reduces the willingness of the individual to consume normal foods in adequate amounts to maintain good health.

Consequently, in this area there is a need for compositions that can be used in AWANA for the treatment or prevention of problems associated with impaired salivation.

The inventors decided to meet this need.

Therefore, the present invention was to provide compositions which are available to all, whom it may be entered without the risk of unwanted side effects, and which is inexpensive and can be used to increase salivary flow, especially in the elderly.

The task was achieved by the object of the invention independent points. Dependent items additionally develop the present invention.

Sialic acid (SiAc) are a family of charged monosaccharide with a chain of nine carbon atoms, derivatives of neuraminic acid (NeuAc). NeuAc is the only sialic acid formed in the body in vivo. As in other vertebrates, for example, are N-glycolylneuraminic acid (NeuGc).

Currently, sialic acid is often used in the field of child nutrition. Currently, sialic acid is often used in the field of child nutrition. For example, the possible participation of SiAc in the cognitive development of children was summarized in the work of Wang (Wang, W. and Brand-Miller, J. (2003) Eur.J.Clin.Nutr. Nov; 57(11): 1351-69). In short, the studies compared infants fed breast milk and infant formula, the software is Aravali, higher content of NeuAc in breast milk, compared with normal infant formula, correlates with an increased content of NeuAc in the saliva and brain babies. However, behavioral effects in the dietary Supplement NeuAc people lack. However, it is assumed that adding to cow's milk NeuAc will give cow's milk attributes of human milk, which may affect brain development in children.

Natural sources rich NeuAc are human milk, elephant milk, Indian Buffalo milk, meat, eggs and fish.

The inventors have introduced sialic acid to old rats. Old animals showed loss of salivary flow compared with young animals. Surprisingly, the feeding of sialic acid leads to increased stimulated the salivation, which is the salivation found in young animals.

Therefore, one embodiment of the present invention is a composition comprising a sialic acid for the treatment and/or prevention of diseases associated with impaired salivation.

The disease is associated with impaired salivation may be selected from the group consisting of dysphagia, xerostomia, and combinations thereof.

Dysphagia is a swallowing disorder characterized by difficulty training is the swallowing mouth, or difficulty in moving material from the mouth to the stomach. It also includes problems in positioning food in the mouth. Dysphagia is due to problems in the nervous or muscular control. It often happens, for example, after a stroke and treatment of cancer head/neck. Dysphagia threatens nutrition and hydration and can lead to aspiration pneumonia and dehydration.

Xerostomia is the medical term meaning a feeling of dry mouth due to decreased function of salivary flow. Chronic dry mouth can be uncomfortable and lead to serious health problems. Dry mouth can cause difficulties in the sensation of taste when chewing, swallowing and speech. If untreated, severe dry mouth can lead to increased levels of dental caries and infections of the mouth, such as candidiasis.

The preferred form of sialic acid is N-acetylneuraminic acid.

N-acetylneuraminic acid has the following synonyms and abbreviations: o-sialic acid; 5-acetamido-3,5-dideoxy-D-glycero-D-galacto-2-nonulosonic acid, 5-acetamido-3,5-dideoxy-D-glycero-D-Galaktionova acid; acetylneuraminic acid, N-acetyl-neuraminic, N-acetylneuraminic acid; NANA and Neu5Ac.

Preferred may be the enrichment of the ingredient and/or composition of sialic acid.

One embodiment n is the standing of the invention consists in the composition, containing protein fraction containing N-acetylneuraminic acid-related peptide/protein skeleton, enriched in threonine, for the treatment and prevention of diseases associated with impaired salivation.

Enrichment threonine means that the content of threonine higher than average prevalence of it in protein mass in humans. For example, the content of threonine can be enhanced at least by 10% compared with the average content of threonine protein mass in humans.

Thus, threonine may be, at least, 6,3 molar % of the amino acids in the protein fraction.

For example, threonine may be present in an amount of from about 8 to 22% of the total number of amino acids.

The protein fraction can optionally contain N-acetylneuraminic acid from about 7 to 25 wt.%.

N-acetylneuraminic acid may be represented in licensesand form. For example, N-acetylneuraminic acid may be represented in the form of related glycoproteins and/or proteoglycans.

In accordance with a particularly preferred embodiment of the present invention containing N-acetylneuraminic acid (NeuAc) protein fraction is characterized peptide/protein skeleton, enriched in threonine (the content of which is from 8 to 22% of the total number of amino acids) and NeuAc, sod the neigh which ranges from 7 to 25 wt.%.

N-acetylneuraminic acid may be represented in the form of oligosaccharide ingredient, which, for example, contains glikozilirovanie amino acids and peptides of the General formula, RnSacmwhere R is an amino acid residue; Sac is a monosaccharide selected from the group containing N-acetylneuraminic acid, N-atsetilgalaktozamin and galactose; n has a value from 1 to 10 with the proviso that if the value of n is 1, R is a residue of threonine or serine, and if n has a value from 2 to 10, the peptide contains at least one residue of threonine or serine; m has a value from 2 to 4; and N-acetylneuraminic acid accounts for at least 15 molar percent of the ingredient.

Preferably n has a value from 1 to 3, a m has a value of 3 or 4.

The ingredient contains at least 15 molar percent of sialic acid, as part sacharides circuit associated with a hydroxyl group of threonine or serine. Sialic acid can be part of a chain, or may itself be a Deputy monosaccharide units in the chain.

Preferably, if oligosaccharide ingredient contains the following monosaccharides: -

ConnectionThe molar percentage
N-acetylase cozamin (GalNAc) 20-25
galactose (Gal)20-25
N-acetylneuraminic acid (NeuAc)40-17,5

Oligosaccharide ingredient may contain from 20 to 25 molar percent of the mixture of serine and threonine.

Oligosaccharide ingredient may contain the following glycosylated amino acids or peptides: -

NeuAc-α-2,3-Gal-β-1,3-(NeuAc-α-2,6-)-GalNAc-Rn

NeuAc-α-2,3-Gal-β-1,3-GalNAc-Rn

Gal-β-1,3-(NeuAc-α-2,6-)-GalNAc-Rn

Gal-β-1,3-GalNAc-Rn

Oligosaccharide ingredient of the invention can be prepared using either joint or sequential hydrolysis of CGMP by ectoprocta and endoproteases to obtain a mixture of free amino acids and peptides with a chain length from 2 to 10 and using nanofiltration hydrolyzed mixture to maintain the fraction having a molecular weight from 1000 to 2000 daltons.

CGMP itself is a byproduct of cheese making, in which whole milk is processed by the enzyme rendina to precipitate casein; In this process CGMP cleaved from K-casein and remains in solution with serum proteins. This product is known as sweet whey. CGMP may be separated from the whey by any method known in this field. A suitable method is described in European Pat is NTE No. 986312.

Without being bound by theory, the authors suggest that the protein fraction containing N-acetylneuraminic acid-related peptide/protein skeleton, enriched in threonine, for example, licensesand N-acetylneuraminic acid, is preferred in comparison with the free N-acetylneuraminic acid, for the following reasons. Free N-acetylneuraminic acid leads to very fast, "sharp" absorption and systemic increase in concentration of N-acetylneuraminic acid runs fast recovery levels of circulating N-acetylneuraminic acid by increased its excretion in the urine. Protein fractions containing N-acetylneuraminic acid-related peptide/protein skeleton, enriched in threonine, avoids this. For example, licensesand N-acetylneuraminic acid reaches all segments of the bowel, leading to slow the “long” absorption of N-acetylneuraminic acid along the entire length of the intestine, including the lower small intestine and large intestine.

The composition may be introduced to the elderly.

The patient is considered "older", if he has survived the first half of his srednegorodskoy in the country of origin of life expectancy, preferably, when he overcame the first two-thirds srednegorodskoy in the country of origin will continue is lnasty life, more preferably, when he overcame the first three quarters srednegorodskoy in his country of origin, life span, it is most preferable if he overcame the first four-fifths srednegorodskoy in his country of origin lifespan.

The composition may be injected into humans or animals, in particular, bedroom animals, domestic animals and/or livestock.

The composition of the present invention may be a food composition, nutraceutical, beverage, dietary Supplement or drug. For example, dietary Supplement or drug can be in the form of tablets, capsules, lozenges, or liquids. Food supplements or medicines are preferably provided in the form of compositions with delayed release, allowing a continuous supply of N-acetylneuraminic acid for a long: period of time.

The composition is preferably selected from the group consisting of products based on milk powder, instant drinks, ready-to-use drinking compositions, nutritional powders, products based on milk, including yogurt or ice cream, cereal products, beverages, water, coffee, cappuccino, malt beverages, flavored chocolate beverages, culinary products, soups, creams, local action suppositories, tablets, syrups, and formulations for transdermal application.

Milk can be any milk available from animal and vegetable sources, and is preferably cow's milk, human milk, sheep milk, goat milk, horse milk, camel milk, rice milk or soy milk.

Instead of milk you can also use protein fraction derived from milk or colostrum.

The composition may further contain protective hydrocolloids (such as gums, proteins, modified starches), binders, film forming agents, encapsulating agents/materials, stenhamra/Obol ochechnogo materials, matrix compounds, coatings, emulsifiers, surfactants, solubilizing agents (oils, fats, waxes, lecithins etc), adsorbents, carriers, fillers, saidinenie, dispersing agents, moisturizing agents, processing AIDS (solvents), intelimouse agents, kusamakura agents, weighting materials, gelling agents, galifornia agents, antioxidants and antimicrobial agents. It may also contain conventional pharmaceutical additives and adjuvants, diluents, including, in particular, water, gelatin of any origin, vegetable gums, ligninsulfonate, talc, sugars, starch, gum Arabic, raise the performance communications oils, the polyalkylene glycols, flavoring agents, preservatives, stabilizers, emulsifiers, buffers, lubricants, colorants, humectants, fillers, etc. in Addition, it may contain organic and inorganic material, suitable for oral or enteral administration as well as vitamins, minerals, and other micronutrients in accordance with the recommendations of the Government, such as the USRDA.

For example, the composition may contain a daily dose of one or more of the following micronutrients ranges: 300-500 mg of calcium, 50-100 mg of magnesium, 150-250 mg of phosphorus, 5-20 mg of iron, 1 to 7 mg of zinc, 0.1 to 0.3 mg copper, 50-200 mcg of iodine, 5-15 mcg of selenium, 1000-3000 ug beta-carotene, 10-80 mg of vitamin G, 1-2 mg vitamin B1, 0.5 to 1.5 vitamin B6, 0.5 to 2 mg vitamin B2, 5-18 mg Niacin, 0.5 to 2.0 micrograms of vitamin B12, 100-800 mcg of folic acid, 30-70 mcg of Biotin, 1-5 μg of vitamin D, 3-10 mcg of vitamin E.

The composition of the present invention may contain a source of protein, a source of carbohydrates and/or fat source.

Can be used any suitable dietary protein, for example, animal proteins (such as milk proteins, meat proteins and egg proteins); vegetable proteins such as soy protein, wheat protein, rice protein and pea protein); a mixture of free amino acids; or combinations thereof. Milk proteins such as casein and whey, and with Evie proteins are particularly preferred. Very positive results for these purposes, the present invention were obtained by the protein fraction containing threonine in an amount of from about 8 to 22% of the total number of amino acids in the protein fraction.

If the composition includes a source of fat, it is more preferable if the source of fat provides from 5% to 40% of the energy mix, for example, 20-30% of energy. Can be added DHA. A suitable profile of the fat may be obtained by using a mixture of canola oil, corn oil and sunflower oil with high oleic acid content.

More preferably, if the source of carbohydrates can deliver 40%-80% of the energy of the composition. Can be used any suitable carbohydrate, for example, sucrose, lactose, glucose, fructose, dried corn syrup, maltodextrin, or a mixture thereof.

In accordance with a particularly preferred embodiment of the present invention containing N-acetylneuraminic acid (NeuAc) protein fraction is characterized peptide/protein skeleton, enriched in threonine (the content of which is from 8 to 22% of the total number of amino acids) and NeuAc, the content of which ranges from 7 to 25 wt.%.

The composition may also contain probiotic microorganism and/or prebiotics such as fructo-oligosaccharides, galactooligosaccharides, pectins and/or their hydrolysates.

Prebiotics are what I particularly preferred in the compositions containing probiotics, because the presence of probiotics and prebiotics produces a synergistic effect.

"Probiotic" means preparations of microbial cells or components of microbial cells with a beneficial effect on health or the health of the host body. (Salminen S, Ouwehand A. Benno Y. et al “Probiotics: how should they be defined” Trends Food Sci. Technol. 1999:10 107-10).

All probiotic microorganisms can be used in accordance with the present invention. Preferably, they are selected from the group consisting of Bifidobacterium, Lactobacillus, Streptococcus and Saccharomyces or mixtures thereof, in particular selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Lactobacillus Acidophilus, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus salivarius, Enterococcus faecium, Saccharomyces boulardii and Lactobacillus reuteri or mixtures thereof, preferably selected from the group consisting of Lactobacillus johnsonii (NCC533; CNCM 1-1225), Bifidobacterium longum (NCC490; CNCM 1-2170), Bifidobacterium longum (NCC2705; CNCM 1-2618), Bifidobacterium lactis (2818; CNCM 1-3446), Lactobacillus paracasei (NCC2461; CNCM 1-2116), Lactobacillus rhamnosus GG (ATCC53103), Lactobacillus rhamnosus (NCC4007; CGMCC 1,3724), Enterococcus faecium SF 68 (NCIMB101415) and mixtures thereof.

Under the "prebiotic" refers to food substances which promote the growth of probiotics in the gut. They are not destroyed in the stomach and in the upper part of the intestine or not adsorb to the LCD tract accepting their persons, but they fermenti is described gastro-intestinal microflora and/or probiotics. Prebiotics, for example, defined in the work of Glenn R.Gibson and Marcel .Roberfroid, Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics, J. Nutr. 1995 125: 1401-1412.

Prebiotics, which can be used in accordance with the present inventions nothing special limited and include all food substances that promote the growth of probiotics in the gut. Preferably, they can be selected from the group consisting of oligosaccharides, optionally containing fructose, galactose, mannose; dietary fiber, particularly soluble fiber, soy fiber; inulin; or mixtures thereof. The preferred prebiotics are fructo-oligosaccharides, galactooligosaccharides, isomaltooligosaccharide, xylooligosaccharide, soybean oligosaccharides, glycosylceramide, lactosucrose, lactulose, platinochloride, maltooligosaccharide, gums and/or their hydrolysates, pectins and/or their hydrolysates.

It was found that the effect of sialic acid in the composition of the present invention will be essentially dependent on the dose. Small quantities will produce smaller effects, and large amounts can be so large that the body will not be able to use all provided SiAc acid. For example, the exact amount provided by SiAc will depend on the patient to be treated and its condition.

Although in General any to icesto SiAc will produce a beneficial effect, it was found that particularly preferred if the sialic acid present in the composition in an amount of 1 mg to 250 mg/g dry weight of the composition.

Sialic acid can be entered in a daily amount of 1 mg to 2 g/kg body weight, preferably of 0.025-0.8 g of body weight of the subject to treatment of the patient.

The person skilled in the art will understand that you can freely combine all the characteristics described here present invention, without departing from the expanded scope of the invention. In particular, the characteristics described for applications of the present invention can be applied to the compositions of the present invention and Vice versa.

Additional advantages and features of the present invention is illustrated in the following examples and figures.

Figures:

The figure 1 shows that older rats show less activity of cholinergic neurons, which is measured by stimulating the production of saliva per unit time, compared to young adult rats, but show a significantly higher neuronal activity upon receipt of a diet rich in sialic acid. Presents mean values and standard error of the mean. N=9-10; ∗ indicates significant difference at p=0,0035 when comparing 3 and 24 months on the control diet and when p=0,0024 when comparing 24 monthly control and sialic (Si) diet on T-test.

Figure 2 again shows that pilocarpine stimulates salivation in young rats (3 m) and old rats (24 m)receiving the control diet (empty columns) or enriched NeuAc diet (filled columns) for 3 weeks. Shown are mean values and standard error of the mean (N=8-10). 2 factory the ANOVA test showed a significant age effect (p=0,0364) and the effects of treatment (p=0,0037) and nearly significant interaction effect (p=0.0550). Please note that the bait NeuAc increases stimulated salivation in old rats is much more efficient than in young adult rats.

Information confirming the possibility of carrying out the invention

Young adult (3 months) and aged rats (24 months old) were fed a semisynthetic diet containing sialic acid in a concentration of 0.15 g/100 g diet (control) or semi-synthetic diet supplemented with sialic acid to a final concentration of 0.9 g/100 g diet (Sia).

After 3 weeks of experimental diet was assessed neuronal activity of cholinergic neurons. To this end, rats were injected with pilocarpine (IE, 1.5 mg/kg body weight for 24 months in rats and 2 mg/kg body weight for 3 months in rats). Pilocarpine is a muscarinic antagonist acting on cholinergic neurons, which leads to salivation. This was chronometrically collection of stimulated saliva. the via is approximately 7 minutes collection stopped.

As seen in figures 1 and 2, old animals showed less stimulated salivary flow compared with young animals. When the consumption of sialic acid old animals reached similar to young animals values of stimulated salivary flow. This indicates that feeding of sialic acid promotes functional recovery of cholinergic neuronal function, which decreases with age.

The findings show that the proper salivation was restored in older animals by providing them with sialic acid through diet approach.

1. The composition of sialic acid, intended for the treatment or prevention of diseases associated with impaired salivation, which contains a protein fraction, which contains from about 7 to 25 wt.% N-acetylneuraminic acid and threonine in an amount constituting from about 8 to 22% of the total number of amino acids, where N is acetylneuraminic acid is linked to a peptide/protein skeleton, enriched in threonine.

2. The composition according to claim 1, in which N-acetylneuraminic acid appears in the form of oligosaccharide ingredient containing glikozilirovanie amino acids and peptides of the General formula, RnSacmwhere R is an amino acid residue, Sac is manasah the reed, selected from the group consisting of N-acetylneuraminic acid, N-atsetilgalaktozamin and galactose, n has a value between 1 and 10 with the proviso that if n is 1, R is a residue of threonine or serine, and if n has a value between 2 and 10, the peptide contains at least one residue is threonine or serine, m has a value from 2 to 4 and at least 15 molar % of an ingredient are N-acetylneuraminic acid.

3. The composition according to claim 1, in which the disease is associated with impaired salivation is selected from the group consisting of dysphagia, xerostomia, and combinations thereof.

4. The composition according to claim 1, which is a pharmaceutical composition, a food product or nutritional Supplement.

5. The composition according to claim 1, which is nutriceutical.

6. The composition according to claim 1, which further comprises necrosadism means; and/or probiotic microorganism and/or a prebiotic.

7. The composition according to claim 6, in which necrosadism tool is an antioxidant plant extract, vitamin or micronutrient.

8. The composition according to claim 6, in which the prebiotic is fructooligosacharides, galactooligosaccharides, pectin and/or its hydrolyzate.

9. The composition according to claim 1, in which N-acetylneuraminic acid is present in the composition in an amount of from 1 mg to 250 mg/g dry matter component is icii.

10. The composition according to claim 1, in which N-acetylneuraminic acid is administered in a daily amount of 1 mg to 2 mg of body weight of the object.

11. The composition according to claim 1, in which the composition is selected from the group consisting of yogurt or ice cream; biscuits; cereal products; muesli bars; water; cappuccino; tea; fruit juices; malt beverages; drinks flavoured with chocolate; soups; confectionery products; chocolate; creams local action; suppositories; tablets and syrups.

12. The composition according to claim 1, which is a product based on milk powder.

13. The composition according to claim 1, which is an instant drink.

14. The composition according to claim 1, which is a ready-to-use drinking part.

15. The composition according to claim 1, which is a nutrient powder.

16. The composition according to claim 1, which is a nutrient liquid.

17. The composition according to claim 1, which is a product based on milk.

18. The composition according to claim 1, which is a grain product.

19. The composition according to claim 1, which is a drink.

20. The composition according to claim 1, which is coffee.

21. The composition according to claim 1, which is a culinary product.

22. The composition according to claim 1, which is a confectionery product.

23. The composition according to claim 1, which is a composition for transdermal application.



 

Same patents:
Dental seal // 2493812

FIELD: medicine.

SUBSTANCE: group of inventions relates to dental seals and methods of their application. Composition of dental seal in form of varnish includes arginine in free form or in form of salt, rosin, white beeswax, mastic, shellac and source of fluoride ions, which is present in composition in concentration, at least 12 wt %, and is selected from group, including tin fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, aluminium fluoride, sodium hydrofluoride, sodium fluoride, calcium fluoride, magnesium fluoride and potassium fluoride. Also claimed is method of treating sensitive teeth, which includes application of said seal composition in form of varnish on tooth of person, requiring treatment, and application of claimed method for improvement of oral cavity health. Application of arginine in said composition of dental seal makes it possible to use fluoride-ions in a larger quantity than is usually used in dental varnishes, without side effects, associated with excess of fluoride-ions.

EFFECT: composition of seal makes it possible to ensure regulated continuous supply of medication.

12 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly to pharmacy and dentistry, and concerns creating new compositions of menthol derivatives. For this purpose, 2-isopropyl-5-methylcyclohexyl-2-hydroxyphenylcarbamate is suggested to be used as an antioxidant, anti-inflammatory and antimicrobial agent for local treatment of the oral cavity, e.g. periodontal diseases. That provides the basis to present the compositions containing an effective amount of 2-isopropyl-5-methylcyclohexyl-2-hydroxyphenylcarbamate, and at least one excipient.

EFFECT: inventions provide treating the oral cavity ensured by an integrated effect on general mechanisms of pathogenesis.

7 cl, 7 tbl, 2 ex, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a method of preventing and treating oral inflammation following a dental surgery, comprising in applying a drug preparation on an incisional wound daily in a patient underwent the implantation procedure and characterised by the fact that the drug preparation used represents a preparation of the strain lactobacillus plantarum 8P-AZ and/or B.bifidum in a dose of at least 10 million live lactic acid bacilli and/or bifidus bacteria.

EFFECT: invention provides simplifying the method of preventing and treating the oral inflammation by making it unnecessary to prepare the drug used if antibiotics are avoided.

2 cl, 9 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to chemical-pharmaceutical and cosmetic industry and represents artificial saliva containing arginine either in the free form, or in the form of a salt together with one or more of: a) a calcium ion source, b) a phosphate ion source, c) a potassium ion source, d) a magnesium ion source, e) a fluoride ion source; f) a flavour stimulating saliva flow; and/or g) a polyol humidifier.

EFFECT: invention provides creating the agent containing arginine or a salt thereof for treating, improving, slowing or preventing dry mouth.

8 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents an agent for local treatment of periodontal diseases, on the basis of organosilicone gycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O, containing therapeutic supplements, differing by the fact that the therapeutic supplements are presented by ketoprofen and methyluracil in the following proportions, wt %: ketoprofen - 0.5 - 1.0; methyluracil - 1.0 - 1.5; organosilicone gycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O - up to 100.

EFFECT: invention provides creating the effective agent applicable in the integrated therapy for treating the inflammatory periodontal diseases.

6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dentistry. Method includes processing perforated root canal and perforation zone with laser irradiation and covering perforation with sealing material. Introduction of light-guide into perforated root canal is carried out. In processing by laser irradiation translational increase of its power parameters is used. During the first session processing is carried out with power 0.5 W, during the second session - 0.75 W, during the third - 1.5 W. Additionally ozone therapy with saturated physiological solution is performed. Time of saturation with ozone is 5 minutes. Concentration of ozone dissolved in physiological solution is 8.8-9.6 mg/l.

EFFECT: method is painless, does not require carrying out local anesthesia, excludes allergic reactions, ensures optimal bactericidal and bacteriostatic effect, which makes it possible to efficiently stop inflammation and reconstruction of bone tissue, reduces number of complications.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to dentistry, and concerns preparations for preventing and treating the diseases of periodontal membrane and oral mucosa. That is ensured by using a pharmaceutical composition in the form of a gel which contains metronidazole benzoate, chlorhexidine gluconate as an active substance and additionally the ingredients specified in a group of alpha-, beta-, gamma-, recombinant interferon.

EFFECT: invention provides reducing the length of treatment in the patients with inflammatory periodontal diseases due to the wide spectrum of action of the composition, prolonged fixation on gums, which accelerates the regeneration of the oral mucosa.

2 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dentistry, and may be used for local therapy of inflammatory periodontal diseases. That is ensured by the daily applications of powdered cellulose surgical cotton on a dentogingival edge after curettage to normalise the microcirculation and hemodynamic values.

EFFECT: method provides higher clinical effectiveness in periodontal diseases, reduced complications and disability periods due to normalising the free radical levels in the damaged tissue while reducing inflammation and accelerating the process of epithelialisation of periodontal tissues.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to compositions for oral cavity care and methods of such compositions application. Claimed composition for oral cavity care contains amorphous quartz and source of ions of bivalent tin, with average size of amorphous quartz particles constituting from 1 to 20 microns. Version of composition additionally includes one or more essential oils and chelant. Method of oral cavity care includes stage, at which upper said composition is introduced into subject's oral cavity.

EFFECT: application of amorphous quartz (fuse quartz) as abrasive in mixture of composition for oral cavity care ensures good compatibility with ions of bivalent tin with effective and safe cleaning of dental tissues.

17 cl, 2 ex, 30 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to composition for oral cavity care and methods of its application. Claimed is composition for oral cavity care, which contains: arginine, in free form or in form of salt in amount from 0.1 to 20 wt % of total composition weight; triclosan in amount from 0.01 to 5 wt % of total composition weight; anionic polymer, which is a copolymer of methyl vinyl ether and maleic anhydrate; anionic surfactant in amount from 0.01 to 10 wt % of total composition weight; soluble fluoride salt in amount from 0.01 to 2 wt % of total body weight, in order to provide 50-25000 ppm of weight of fluoride ions, in which soluble fluoride salt or source of fluoride ions is selected from sodium fluoride, sodium monofluorophosphate and their mixtures; and abrasive material, which contains fraction of minor particles, constituting at least about 5 wt % of total composition weight, and in said fraction minor particles have average diameter d50 smaller than 5 mcm.

EFFECT: application of composition for oral cavity care along with improved delivery of antibacterial agent provides additional advantages in acceleration of remineralisation and restoration of precarious affection foci due to combination of fluoride and arginine, as well as due to application of finely disperse abrasive as composition component.

11 cl, 1 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: intratympanic composition used for treating an ear disease contains: (a) an antimicrobial agent consisting of a number of particles; and (b) a polyoxyethylene and polyoxypropylene copolymer; the composition (i) is a liquid at room temperature; (ii) has a gelling point within the range of 19°C to 42°C; (iii) has a gel viscosity of 15000 sP to 1000000 sP; (iv) has an osmolarity less than 1000 mOsm/l; and the intratympanic composition release the antimicrobial agent in an ear for at least 5 days, and it is introduced at room temperature.

EFFECT: effective treatment of the ear diseases; the composition is non-toxic and has a non-irritating effect on the ear structures, provides the permanent prolonged release of the active agent with a reduced dose rate and reduces the risk of a potential tympanum damage.

13 cl, 9 tbl, 5 dwg, 30 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine, namely to a pharmaceutical composition for topical administration used to prevent the viral infections caused by DNA-containing viruses. As active ingredients, the pharmaceutical composition contains 0.001-5.0 wt % of deoxyribonuclease (DNA-ase) and 0.000001-5.0 wt % of alpha-fetoprotein and 0.001-5.0 wt % of glycyrrhizinic acid or a salt thereof: ammonium or dipotassium or trisodium glycyrrhizinate; the carriers are as follows: β-cyclodextrins 0.001-5.0 wt %, 0.05-1.0 wt % of a polymer carrier, and pharmaceutically acceptable carriers or excipients. In addition, the composition can contain 0.001-5.0 wt % of dexpanthenol or sangviritrin, 0.001 -5.0 wt % of ascorbyl palmitate or escin.

EFFECT: invention provides improved stability, potentiated complex antiviral effect.

2 cl, 6 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, and concerns an iRNA agent for reducing the levels of viral protein, iRNA, or respiratory syncytial virus titre in an individual's respiratory cell. The present iRNA agent contains a sense chain and an antisense chain, wherein the above sense chain comprises at least 15 consecutive nucleotides complementary to the gene P of the RSV virus, and the antisense chain comprises at least 15 consecutive nucleotides complementary to said sense chain, wherein said antisense chain comprises 15 or more consecutive nucleotides of a sequence consisting of nucleotides 1-19 of the sequence SEQ ID NO:6.

EFFECT: invention may be used in treating the respiratory diseases and preparing the RSV vaccines.

8 cl, 5 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a therapeutic agent of acadesine with high anti-cancer activity, containing acadesine, as well as a non-steroid anti-inflammatory preparation: ibuprofen, or indomethacin, or aspirin.

EFFECT: what is shown is synergetic anti-cancer action of the claimed agent on a B-cell leukaemia model.

3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and aims at prevention of the purulent complications of pancreatonecrosis. Patient's intestinal mucosal permeability is evaluated by the mannitol/lactulose test. If the urine mannitol/lactulose relation falls within the range of 0.03 to 0.05, a nasojejunal catheter is used to introduce 0.25% Derinat 10ml dissolved in physiological saline 50 ml into the intestine. If the urine mannitol/lactulose relation exceeds 0.05, 0.25% Derinat 20ml dissolved in physiological saline 50 ml is introduced into the intestine using the nasojejunal catheter. The preparation is introduced once a day for 3-4 days.

EFFECT: method enables more effective prevention of the purulent complications of pancreatonecrosis with the improved intestinal mucosa permeability.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, veterinary science and pharmaceutical industry. The invention provides using triterpene glycosides from holothuria that is frondoside A or a complex of frondoside A and cholesterol as an agent for inhibiting the multiple drug resistance of tumour cells, and for preparing a pharmaceutical composition inhibiting the multiple drug resistance of tumour cells.

EFFECT: using the invention enables extending the range of products inhibiting the multiple drug resistance of tumour cells.

2 cl, 4 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and may be used to treat viral ocular diseases. That is ensured by the interferon (INF) status assay, namely evaluating alpha-INF production, gamma-INF production, serum INF titre, spontaneous INF in the reaction in vitro. The derived data collection and the presence of clinical manifestations enable stating the viral diseases thereby choosing the therapeutic approach.

EFFECT: invention enables normalising the interferon status in the patients with the viral ophthalmic diseases.

4 ex

FIELD: medicine.

SUBSTANCE: there are presented: a liposomal preparation for the pulmonary delivery, wherein the liposomes a surface of which is modified by at least one polymer specified in a group consisting of terminally hydrophobisated polyvinyl alcohols and chitosan, an encapsulated gene, a method for preparing and a method of treating a pulmonary tissue disease involving the stage of administering the above liposomal preparation into the patient's lung. It has been shown that the liposome modified by terminally hydrophobisated polyvinyl alcohol may be kept on the pulmonary tissue surface for a long time.

EFFECT: high effectiveness of the pulmonary delivery of the claimed liposomal preparation for a relatively short time.

10 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology, and may be used for treating non-Hodgkin lymphomas. That is ensured by sampling an intramedullary suspension 100-200 ml into a bottle containing the haemopreserving agent Glugicirum 50-70 ml. The prepared suspension is added with the chemopreparation doxorubicin 50 mg/m2. It is incubated at t +37°C for 40 minutes. Then it is introduced intravenously drop-by-drop. The intramedullary suspension is sampled during the second and fourth chemotherapeutic course.

EFFECT: invention enables reducing a rate of toxic responses and complications accompanying the chemopreparation therapy.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to a composition for relieving and/or treating musculoskeletal, articular and juxta-articular diseases, and painful muscle spasm. A pharmaceutical composition for relieving and/or treating musculoskeletal, articular and juxta-articular diseases, and painful muscle spasm, wherein the above composition is presented in the form of a solid dosage form containing a combination of ketoprofen and thiocolchicoside found in the free form or in the form of a salt, in the absence of direct contact in between when mixing the composition. Using the for relieving and/or treating the musculoskeletal and articular diseases, including ankylosing spondylitis, low back pain, osteoarthritis and rheumatoid arthritis, and the juxta-articular diseases, such as bursitis and tendonitis and painful muscle spasm. A method for preparing a tablet dosage form for relieving and/or treating the musculoskeletal, articular and juxta-articular diseases, and painful muscle spasm (versions).

EFFECT: composition is stable and characterised by the low impurity level.

11 cl, 5 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out hernia removal in intralaminar way. Posterior longitudinal ligament defect is covered with Tacho-Comb plate after having done disk cavity curettage. Subcutaneous fat fragment on feeding pedicle is brought to dorsal surface of radix and dural sac.

EFFECT: enhanced effectiveness of treatment; reduced risk of traumatic complications.

1 dwg

Up!